RPRD Diagnostics Announces Strategic Collaboration with Children's Minnesota to Advance Clinical Pharmacogenomics

Feb. 13, 2017 MILWAUKEE, WI

RPRD Diagnostics today announced a collaboration with Children's Minnesota dedicated to implementing a pharmacogenomic testing process.  RPRD Diagnostics is a privately-held precision medicine company specializing in comprehensive pharmacogenomics (PGx) testing and analysis. RPRD aims to advance clinical pharmacogenomic testing. By implementing this process the aim is to ensure patients get the right medication at the right time, making care more precise and more affordable.

"Comprehensive pre-emptive pharmacogenomic testing is the cornerstone of precision medicine, especially in pediatrics, and RPRD Diagnostics is a pioneer in this area," said Nancy Mendelsohn, MD, senior medical director of specialty care at Children's Minnesota. "Collaborating with RPRD Diagnostics underscores our commitment to integrating pharmacogenomic medicine into the care of our patients, with the goal of providing better care and better outcomes."

Through this new collaboration, Children's Minnesota will begin using the RPRD Diagnostic platform within the cancer and blood disorder clinic as well as within the neurology-psychology practice. Clinical specialists at the Children's Minnesota genomic medicine program will work closely with RPRD Diagnostics in the implementation of this innovative service.  

"We are a science-driven company focused on innovation, and we are excited to work together with Children's Minnesota," said Ulrich Broeckel, MD, founder and CEO of RPRD Diagnostics. "They have made substantial commitments toward implementing pharmacogenomics for their patients and are leading the way as a premiere pediatric healthcare provider. Historically, the application of pharmacogenetics has been limited by the high cost and limited scope of available tests—two barriers that RPRD Diagnostics has overcome. We appreciate that Children's Minnesota sees the value in our comprehensive test panels."

About RPRD Diagnostics

RPRD ('Right Person Right Drug') Diagnostics is dedicated to offering health care providers comprehensive pharmacogenomic testing and analysis services.  This information will aid health care providers in their clinical decision-making and help improve patient outcomes. These tests will help physicians make determinations about the safest drug treatment for their patients, taking into account the patient's unique genetic profile against relevant genomic insights and therapeutic approaches. The company's founder, scientific advisors, and technical team are industry leaders in genomics technology, pharmacogenetic testing, and clinical implementation of genetic testing. The company's mission is to enable precision medicine in routine clinical practice. For more information, please visit the company's website at www.rprdx.com, and follow us on Twitter @RPRDx.

About Children's Minnesota

Children's Minnesota is the seventh largest pediatric health system in the United States and the only health system in Minnesota to provide care exclusively to children, from before birth through young adulthood. An independent and not-for-profit system since 1924, Children's serves kids throughout the Upper Midwest at two free-standing hospitals, 12 primary and specialty-care clinics and six rehabilitation sites. Children's maintains its longstanding commitment to the community to improve children's health by providing high-quality, family-centered pediatric services and advancing those efforts through research and education. This work is made possible in large part by generous philanthropic and volunteer support from individuals and organizations throughout the state and region. An award-winning health system, Children's is regularly ranked by U.S. News & World Report as a top children's hospital. Please visit childrensMN.org.

Media Contacts: 
Joleen Rau
Rau Communications LLC
(608) 209-0792  
jrau@raucommunications.com

RPRD Diagnostics Partners with St. Jude Children's Research Hospital to Offer Comprehensive Pharmacogenetics Testing

Oct. 19, 2017 MILWAUKEE, Wis. and MEMPHIS, Tenn.

RPRD (Right Patient Right Drug) Diagnostics, a privately-held, Wisconsin-based precision medicine company, today announced a collaboration with St. Jude Children's Research Hospital.  RPRD Diagnostics will perform preemptive, comprehensive clinical pharmacogenetics testing for St. Jude's PG4KDS program.

St. Jude Children's Research Hospital is a leader in pre-emptive pharmacogenetics and its implementation into clinical care, especially for pediatric oncology and hematology.  Under their PG4KDS program, every St. Jude patient is eligible to receive comprehensive pharmacogenetic testing, usually at the beginning of his or her treatment.  The results are entered into the patient's electronic medical record, enabling clinicians to utilize this information when choosing and dosing a drug.

RPRD's collaboration with St. Jude utilizes the comprehensive pharmacogenomics genotyping platform PharmacoScan™ Solution from Thermo Fisher Scientific. Launched in 2016, the PharmacoScan platform was developed in collaboration with pharmacogenomics consortia and Ulrich Broeckel, MD, founder and CEO of RPRD Diagnostics and a key collaborator on its content selection. The platform can interrogate with one single assay more than 4,600 markers in nearly 1,200 genes.

RPRD Diagnostics cost-effective pharmacogenomics testing improves upon traditional, widely used tests that screen just a limited set of genes. The Company's tests provide support for clinicians to make decisions about the safest drug treatment for their patients, taking into account the patient's unique genetic profile. Tailoring treatments in this way can improve patient outcomes, reduce the risk of negative drug reactions and lower overall costs.

"We are excited that St. Jude has chosen RPRD Diagnostics as their reference laboratory for comprehensive pharmacogenetics testing, and we appreciate their confidence in our testing platform and expertise. St. Jude and RPRD share a common vision for implementing preemptive pharmacogenetic testing in clinical care," said Dr. Broeckel, who is also a lead researcher and professor of pediatrics, medicine and physiology, and an associated director at the Genomic Sciences and Precision Medicine Center at the Medical College of Wisconsin, as well as an investigator at the Children's Hospital of Wisconsin Research Institute. "In addition to offering comprehensive testing services, we are pleased to serve as a reference lab for the St. Jude Total XVII clinical trial for patients with acute lymphoblastic leukemia or lymphoma.  Our recently launched CNT™ Panel offers testing targeted at these diseases and provides results that will be used to adjust drug dosing as part of the clinical trial."

"We are excited about collaborating with RPRD and utilizing the PharmacoScan platform because it includes more of the genomic variants that are considered actionable for prescribing decisions based on Clinical Pharmacogenetics Implementation Consortium (CPIC®) guidelines," said Mary Relling, Pharm.D., principal investigator of the PG4KDS program and Chair of the Pharmaceutical Department at St. Jude. "This means we will be able to provide guidance to our prescribers for more medications going forward."

"We are extremely proud to have the PharmacoScan Solution being offered for routine use in clinical research on samples from St. Jude Children's Research Hospital," said Shantanu Kaushikkar, Director Genotyping Microarrays at Thermo Fisher Scientific. "RPRD has been a fantastic longstanding partner in the development and launch of the PharmacoScan platform, and we are excited to see the product being used in preemptive pharmacogenetics. We look forward to working with both RPRD Diagnostics and St. Jude in this exciting phase in pharmacogenetic testing for the PG4KDS program."

About RPRD Diagnostics
RPRD (Right Patient Right Drug) Diagnostics is a precision medicine company offering clinical pharmacogenomics (PGx) testing and analysis services to healthcare providers and pharmaceutical companies. Results from RPRD Diagnostic's PGx tests are used by healthcare providers to support clinical decision-making, thereby improving patient outcomes and reducing costs. The company specializes in both comprehensive PGx and tailored panels, such as the CNT™ Panel for identification of leukemia patients at risk for toxicity from thiopurine drugs. These tests enable physicians to consider a patient's unique genetic profile when recommending drug treatment. See www.rprdx.com.

About St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude is ranked the No. 1 pediatric cancer hospital by U.S. News & World Report. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

Media Contacts:

RPRD Diagnostics
Joleen Rau (608) 209-0792  
181330@email4pr.com

St. Jude Media Relations Contacts
Marvin Stockwell
Desk: (901) 595-0445
Cell: (901) 734-8766
181330@email4pr.com

Michael Sheffield             
Desk: (901) 595-0221
Cell: (901) 379-6072
181330@email4pr.com


Wisconsin, South Korean Biotech Companies Agree to Collaborate on Expanding Pharmacogenomics Testing Services in South Korea

RPRD Diagnostics, Orient Bio sign agreement during Governor Walker’s trade mission

 

SEOUL, SOUTH KOREA, FEB. 13, 2017 —

RPRD (Right Patient Right Drug) Diagnostics, a privately-held, Wisconsin-based precision medicine company, today announced a strategic partnership with Orient Bio Inc., a leading South Korean biotechnology company.

An agreement signed during Governor Scott Walker’s trade mission to South Korea calls for establishing a business plan in which RPRD Diagnostics will expand the availability of its advanced pharmacogenomics (PGx) testing services into new markets and Orient Bio will diversify its business into new areas, including precision medicine and clinical PGx.

“This new partnership will not only benefit both companies, but it represents the many opportunities that exist for future collaborations between South Korea and Wisconsin,” said Governor Walker, who oversaw a ceremony in which the companies signed a memorandum of understanding. “More importantly, this joint initiative has the potential to improve health-care outcomes as well as patients’ lives.”

RPRD Diagnostics’ PGx tests help physicians make decisions about the safest drug treatment for their patients, taking into account the patient's unique genetic profile. Tailoring treatments in this way can improve patient outcomes, reduce the risk of negative drug reactions and lower overall costs. RPRD Diagnostics, based in Wauwatosa, has developed cost-effective PGx tests, screening thousands of known genetic variants that improve upon traditional, widely used tests that screen just a handful.

"Orient Bio recognizes the value of our next-gen pharmacogenomics testing approach and the opportunity to improve healthcare in South Korea," said Ulrich Broeckel, MD, founder and CEO of RPRD Diagnostics. "Of particular interest is our recently launched CNT™ Panel, which is highly relevant for patients of East Asian ethnicity who may receive thiopurine drug treatment, prescribed for patients with leukemia in addition to other diseases." 

Dr. Broeckel is a lead researcher and professor of pediatrics, medicine and physiology at the Medical College of Wisconsin, which is the largest research institution in the Milwaukee area and second largest in Wisconsin.

"Our company has established a very successful business supplying many products and services to drug development and life science markets, thus the partnership with RPRD Diagnostics allows us to build upon previous success while also extending our business into clinical diagnostics," said Dr. Jaejin Chang, President and CEO of Orient Bio. "Dr. Broeckel and his team are looking ahead to a future where pharmacogenomics testing is part of routine clinical care, and Orient Bio shares that vision."

The memorandum of understanding was signed Friday in Seoul by Dr. Broeckel and Dr. Chang. In addition to Governor Walker, also attending the signing ceremony was Katy Sinnott, vice president of International Business Development for the Wisconsin Economic Development Corporation (WEDC).

The agreement was signed as part of Governor Walker’s trade mission to Japan and South Korea. The governor is leading a 22-member delegation that includes WEDC leaders and executives from eight Wisconsin companies. The governor will return to Wisconsin on Saturday.

About RPRD Diagnostics

RPRD (Right Patient Right Drug) Diagnostics is a precision medicine company offering clinical pharmacogenomics (PGx) testing and analysis services to healthcare providers and pharmaceutical companies. Results from RPRD Diagnostic’s PGx tests are used by healthcare providers to support clinical decision-making, thereby improving patient outcomes and reducing costs. The company specializes in both comprehensive PGx and tailored panels, such as the CNT™ Panel for identification of leukemia patients at risk for toxicity from thiopurine drugs. These tests enable physicians to consider a patient's unique genetic profile when recommending drug treatment. For more information, see www.rprdx.com.

About Orient Bio

Orient Bio Inc., founded in 1959, is a leading South Korean biotechnology company that produces and supplies a broad range of catalog products, including animal models, laboratory supplies and medical equipment. Additionally, as a contract research organization (CRO), Orient Bio offers pre-clinical services in support of drug development, including generation of transgenic animal models, safety and toxicology testing, and genetic testing. As a successful conglomerate, Orient Bio subsidiaries provide products in support of other industries, such as feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines.

Media Contacts: 

For Governor Walker
Tom Evenson, (608) 266-2169
tom.evenson@wisconsin.gov

For RPRD Diagnostics
Joleen Rau (608) 209-0792  
jrau@raucommunications.com

For Orient Bio
Paul Kim 82-10-8210-8760  
sangnyun.kim@orientbio.co.kr

RPRD Diagnostics Launches to Bring Comprehensive Pharmacogenetics Testing to Routine Clinical Practice

MILWAUKEE – October 17, 2016 —

RPRD (Right Person Right Drug) Diagnostics today announced its founding as a spin-off from the Medical College of Wisconsin (MCW). As a precision medicine company, RPRD Diagnostics is focused on providing comprehensive pharmacogenetics testing services, which analyze patients’ genomes for variations that are known to impact drug safety and efficacy, in a CLIA-certified lab. Bringing a cost-effective genetic screening service into routine clinical practice will enable health care providers to tailor drug prescriptions to individual patients.

The company, headquartered in Milwaukee, will develop clinical laboratory tests using next-generation microarray platforms and other advanced technologies. RPRD Diagnostics' unique services enable health care providers to preemptively screen a patient's genome for variations known to impact the performance or metabolism of a drug. Tailoring treatments in this way can improve patient outcomes, reduce the risk of adverse drug reactions, and lower overall costs. Additionally, the company provides supporting services for interpretation of patient genetic data and integration into electronic medical record (EMR) systems.

"Over the past decade, there have been major advances in pharmacogenetics, improving our understanding of how genetics contribute to an individual's response to a drug. Unfortunately, these advances have not been widely implemented due to the high cost and narrow scope of currently available tests," said Ulrich Broeckel, MD, Founder and Chief Executive Officer of RPRD Diagnostics and professor of pediatrics, medicine and physiology at MCW.

RPRD Diagnostics specializes in offering comprehensive pharmacogenetics testing services that survey thousands of clinically actionable gene variants in parallel and provides the necessary interpretation and integration into the client's EMR systems. The company is able to achieve this goal, and at a per-variant cost far below competitors, by leveraging new technology platforms developed internally and by various partners. “With the current shift toward precision medicine, and the industry focus on improving patient outcomes," said Dr. Broeckel, "RPRD Diagnostics offers unique and cost-effective solutions to help our clients develop value-based business models and to improve patient care.”

William Clarke, MD, Director of Research Commercialization and part of the Office of Technology Development at MCW, said, “It was exciting to assist Dr. Broeckel in the development of his new company. I am convinced that RPRD Diagnostics will bring important new clinical insights to the care of patients. This company, along with our prior spin-off companies, shows the deep expertise that MCW has in genetics."

About RPRD Diagnostics

RPRD (Right Person Right Drug) Diagnostics is dedicated to offering health care providers with comprehensive pharmacogenetic testing and analysis services to inform clinical decisions and improve patient outcomes. These tests will help physicians make determinations about the best drug treatment for each patient, taking into account the patient’s unique genetics against relevant genomic insights and therapeutic approaches. The company’s founder, scientific advisors, and technical team are world leaders in genomics technology, pharmacogenetics testing, and clinical implementation of genetic testing. The company's mission is to enable precision medicine in routine clinical practice. For more information, please visit the company’s website at www.rprdx.com, and follow us on Twitter @RPRDx.

About Medical College of Wisconsin

The Medical College of Wisconsin is the state’s only private medical school and health sciences graduate school.  Founded in 1893, it is dedicated to leadership and excellence in education, patient care, research and community engagement.  More than 1,200 students are enrolled in MCW’s medical school and graduate school programs in Milwaukee, 56 medical students enrolled at MCW-Green Bay, and 26 students matriculated to MCW-Central Wisconsin in 2016.   MCW’s School of Pharmacy will open in 2017 or 2018 with an initial class size of 60 students.  A major national research center, MCW is the largest research institution in the Milwaukee metro area and second largest in Wisconsin.  In FY 2014-15, faculty received approximately $158 million in external support for research, teaching, training and related purposes, of which approximately $139 million is for research.  This total includes highly competitive research and training awards from the National Institutes of Health (NIH).  Annually, MCW faculty direct or collaborate on more than 3,200 research studies, including clinical trials. Additionally, more than 1,500 physicians provide care in virtually every specialty of medicine for more than 525,000 patients annually.

###

MEDIA CONTACTS:

RPRD Diagnostics
Joleen Rau
Rau Communications LLC
(608) 209-0792
jrau@raucommunications.com
 
Medical College of Wisconsin
Maureen Remmel
Brand Affiliations and Partnerships Manager
Office of Communications
Medical College of Wisconsin
(414) 955-4744  
mremmel@mcw.edu